Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer

DANBURY, Conn., May 20 /PRNewswire-FirstCall/ -- Biodel Inc.
(Nasdaq: BIOD) today announced that Alan Krasner, M.D. has been appointed as
the Company's Chief Medical Officer, effective May 27, 2008.
"The addition of Dr. Krasner to our team provides Biodel with strong
internal clinical and regulatory leadership and we expect him to play an
important role in the clinical development of our product candidates," said
Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Dr.
Krasner's depth of knowledge in endocrinology and insulin, coupled with his
experience developing late stage drug candidates will be valuable in advancing
our suite of VIAject(TM) products to market."
Dr. Andreas Pfuetzner, Biodel's current Chief Medical Officer will remain
on Biodel's management team as the Company's Chief Medical Officer in Europe
and as a member of the Company's Scientific Advisory Board.
"I look forward to working closely with my esteemed colleague to advance
VIAject(TM) through the NDA phase of development," said Professor Dr. Andreas
Pfuetzner.
Dr. Krasner joins the Company from Pfizer Global Research and Development
where he was Director of the Department of Clinical Research Metabolic
Diseases and responsible for the design, execution, clinical analysis, and
reporting of multiple, global clinical trials supporting registration of late
stage drug candidates. Dr. Krasner currently serves as a consulting physician
at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial
Hospital in New London, Connecticut. Dr. Krasner holds a B.S. from the
Medical Education Honors Program at Northwestern University and a M.D. from
Northwestern University Medical School. He completed his residency at Johns
Hopkins Hospital in internal medicine and subsequently received a fellowship
from Johns Hopkins Hospital in endocrinology and metabolism.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for endocrine
disorders, such as diabetes and osteoporosis. Biodel's product candidates are
developed by using VIAdel(TM) technology, which reformulates existing
FDA-approved peptide drugs. The Company's lead product candidate,
VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in
development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM)
is currently being tested in two pivotal Phase III clinical trials. Biodel's
pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin
in the Phase I stage of clinical testing, and two pre-clinical osteoporosis
product candidates. For further information regarding Biodel, please visit
the Company's website at www.biodel.com.
BIOD-G
SOURCE Biodel Inc.

Investors: Rebecca Der, rder@burnsmc.com, or Media: Carney Noensie,
cnoensie@burnsmc.com, both of Burns McClellan, Inc., +1-212-213-0006, for
Biodel Inc.